← Back to Search

Behavioural Intervention

TMS for Methamphetamine Abuse

N/A
Recruiting
Led By Sooraj John, M.D.
Research Sponsored by Carilion Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline/visit 2, day 5 of itbs/sham tms, 3 days after-, 1 week after-, 2 weeks-after, and one month after completion of itbs/sham tms
Awards & highlights

Summary

This trial is using a treatment called Transcranial Magnetic Stimulation (TMS) to see if it can help with treating Methamphetamine Use Disorder. People with this disorder will receive 5 TMS

Who is the study for?
This trial is for individuals struggling with Methamphetamine Use Disorder. Participants will be randomly assigned to receive either real TMS treatment or a sham (placebo) version over five consecutive sessions.Check my eligibility
What is being tested?
The study is testing the effectiveness of Transcranial Magnetic Stimulation (TMS), a non-invasive brain stimulation technique, in treating Methamphetamine Use Disorder compared to a sham procedure that mimics TMS without active treatment.See study design
What are the potential side effects?
TMS may cause discomfort at the site of application, headache, lightheadedness, or seizures in rare cases. The sham procedure should have fewer effects since it's designed to mimic TMS without delivering actual stimulation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~screening/visit 1, baseline/visit 2, day 5 of itbs/sham tms, 3 days after-, 1 week after-, 2 weeks-after, and one month after completion of itbs/sham tms
This trial's timeline: 3 weeks for screening, Varies for treatment, and screening/visit 1, baseline/visit 2, day 5 of itbs/sham tms, 3 days after-, 1 week after-, 2 weeks-after, and one month after completion of itbs/sham tms for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Stimulant Craving Questionnaire (STCQ)
Urine Drug Screen (UDS)
Secondary outcome measures
Clinical Global Impression - Improvement (CGI-I)
Clinical Global Impression - Severity (CGI-S)
Generalized Anxiety Disorder-7 (GAD-7)
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Transcranial Magnetic Stimulation (TMS)Experimental Treatment1 Intervention
This arm receives the TMS treatments.
Group II: Sham-TMSPlacebo Group1 Intervention
This arm receives sham TMS treatments.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulation
2017
Completed Phase 4
~730

Find a Location

Who is running the clinical trial?

Carilion ClinicLead Sponsor
74 Previous Clinical Trials
13,022 Total Patients Enrolled
Virginia Polytechnic Institute and State UniversityOTHER
146 Previous Clinical Trials
28,413 Total Patients Enrolled
Sooraj John, M.D.Principal InvestigatorCarilion Clinic
~15 spots leftby Dec 2024